FibroGen (NASDAQ:FGEN) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of FibroGen (NASDAQ:FGEN) in a research note released on Saturday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of FibroGen in a report on Tuesday, March 18th.

FibroGen Stock Down 6.4 %

NASDAQ:FGEN opened at $0.32 on Friday. The company’s 50 day moving average price is $0.49 and its 200-day moving average price is $0.43. FibroGen has a 52 week low of $0.18 and a 52 week high of $2.80. The stock has a market cap of $31.74 million, a price-to-earnings ratio of -0.26 and a beta of 0.82.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.08) EPS for the quarter, meeting analysts’ consensus estimates of ($0.08). The firm had revenue of $3.14 million for the quarter, compared to analysts’ expectations of $24.91 million. As a group, sell-side analysts anticipate that FibroGen will post -0.8 earnings per share for the current year.

Institutional Investors Weigh In On FibroGen

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. boosted its holdings in FibroGen by 430.7% in the third quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock worth $668,000 after purchasing an additional 1,358,194 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in FibroGen by 80.4% in the fourth quarter. Renaissance Technologies LLC now owns 1,358,712 shares of the biopharmaceutical company’s stock worth $719,000 after purchasing an additional 605,572 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of FibroGen by 3.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock worth $433,000 after acquiring an additional 32,884 shares during the last quarter. Two Sigma Advisers LP boosted its stake in shares of FibroGen by 18.3% during the 4th quarter. Two Sigma Advisers LP now owns 878,400 shares of the biopharmaceutical company’s stock worth $465,000 after acquiring an additional 135,600 shares during the last quarter. Finally, Two Sigma Investments LP boosted its stake in shares of FibroGen by 19.6% during the 4th quarter. Two Sigma Investments LP now owns 604,421 shares of the biopharmaceutical company’s stock worth $320,000 after acquiring an additional 98,888 shares during the last quarter. Hedge funds and other institutional investors own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.